Cell Line-Derived Xenograft (CDX) Models Development for Preclinical Cancer Research
Cell line-derived xenograft (CDX) models provide a robust, scalable, and validated platform for initial anti-cancer efficacy screening. At Alfa Cytology, we harness the power of these essential models to accelerate your therapeutic pipeline, delivering the clear, decision-driving data needed to advance your lead candidates.
Introduction to CDX Models
The process is initiated by culturing a specific cancer cell line in vitro to ensure a sufficient number of viable cells for implantation. Next, these cells are typically injected subcutaneously into immunodeficient mice, whose compromised immune system allows for successful engraftment of the foreign cells. Following a period of growth and careful monitoring, the resulting palpable tumors reach a specified size, at which point the CDX model is ready for therapeutic evaluation.
Fig.1 Schematic of CDX model development.
Tumor Cell Lines
Alfa Cytology offers a broad portfolio of well-validated cell line-derived xenograft (CDX) models across various cancer types to robustly evaluate the efficacy of novel therapeutics. Complementing this collection, we provide numerous cell lines stably expressing fluorescent reporters, enabling real-time in vivo imaging to dynamically visualize tumor growth and therapeutic response.
| Cancer | Cell Lines |
| Lung Cancer | NCI-H1299, PC-9, NCI-H1975, NCI-H460, A549, Calu-3, NCI-H23, HCC827, NCI-H1703, NCI-H441, NCI-H1650, NCI-H292, NCI-H520, NCI-H446, NCI-H2228, NCI-H69, NCI-H226, EBC-1, CORL23 |
| Colorectal Cancer | COLO205, HT29, LOVO, HCT116, SW620, SW480, HCT-15, DLD-1, LS174T, CL-34, RKO, KM12 |
| Bladder Cancer | 5637, UMUC3, RT4, SW-780, RT112 |
| Lymphomas | Raji B, Ramos, REC-1, Daudi, DoHH-2, Granta 519, HUT-78, KARPAS-299, Namalwa, SU-DHL-4 |
| Breast Cancer | MDA-MB-231, BT474, MCF-7, MDA-MB-468, MDA-MB436, HCC-1806, HCC-1954, HCC70, JIMT-1 |
| Ovarian Cancer | SK-OV-3, OVCAR-3, Caov-3, A2780, AG6000, BG1, IGR0V1, OVCAR-4, OVCAR-5, OVSAHO |
| Gastric Cancer | HGC-27, MGC803, MKN45, NCl-N87, NUGC-3, NUGC-4, AGS, 3011, FU97, IM95, MKN1, N87 |
| Kidney Cancer | 786-O, caki-1, ACHN |
| Liver Cancer | HepG2, HUH-7, Hep3B, SK-HEP-1, SNU-398, SNU-449, SS49, SNU-739, SNU-761,SNU-878 |
| Pancreatic | AsPC-1, PANC-1, BxPC-3, HPAF-II, CFPAC-1, BxPc-3, Capan-1, Capan-2, HPAC, KP4, MIA PaCa-2 |
| More | …… |
Case Study: BT474 Xenograft Model
To establish a dose-dependent BT474 xenograft model, female NU/NU mice were subcutaneously inoculated on the right flank with 1×105, 1×106, or 1×107 BT474 cells, each suspended in a 100 µL volume of PBS and matrigel (1:1 ratio). Subsequent monitoring revealed a clear, dose-dependent acceleration in tumor volume corresponding to the initial cell count, while a slight decrease in body weight was observed in groups with higher tumor burden.
Tumor Volume
Tumor Volume
The expert scientific team at Alfa Cytology leverages a robust portfolio of CDX models to accelerate preclinical drug evaluation and drive your oncology programs forward. We invite you to contact with our specialists to discuss your project, and we will partner with you to develop a bespoke study design tailored to your unique research goals.
Reference
[1] EINI M, ZAINODINI N, MONTAZERI H, et al. A Review of Therapeutic Antibodies in Breast Cancer [J]. Journal of Pharmacy & Pharmaceutical Sciences, 2021, 24(3): 363-80.